These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 7586289)

  • 21. Myocardial 18F-FDG-PET. Experiences with the euglycemic hyperinsulinemic clamp technique.
    Locher JT; Frey LD; Seybold K; Jenzer H
    Angiology; 1995 Apr; 46(4):313-20. PubMed ID: 7726451
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Positron emission tomography in the diagnosis and management of coronary artery disease.
    Bratton NG
    J La State Med Soc; 1995 May; 147(5):193-6. PubMed ID: 7782672
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Quantification of patterns of regional cardiac metabolism.
    Lear JL; Ackermann RF
    Radiology; 1990 Sep; 176(3):659-64. PubMed ID: 2389023
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Detection of myocardial viability with positron emission tomography in a patient with ischemic cardiomyopathy.
    J Nucl Med; 1991 Jan; 32(1):130-5. PubMed ID: 1988617
    [No Abstract]   [Full Text] [Related]  

  • 25. Fluorodeoxyglucose (FDG) and tumour metabolism.
    Van Wyngaarden KE; Pauwels EK
    Nucl Med Commun; 1995 Dec; 16(12):987-9. PubMed ID: 8719978
    [No Abstract]   [Full Text] [Related]  

  • 26. Re-evaluation of myocardial FDG uptake in hyperglycemia.
    Kubota K; Kubota R; Yamada S; Tada M; Takahashi T; Iwata R
    J Nucl Med; 1996 Oct; 37(10):1713-7. PubMed ID: 8862317
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Simple method to quantify myocardial glucose metabolism from MB ratio in myocardial FDG PET.
    Nishikawa J; Ohtake T; Yokoyama I; Watanabe T; Momose T; Sasaki Y
    Ann Nucl Med; 1996 Aug; 10(3):323-8. PubMed ID: 8883708
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Metabolic mismatch of septal beta-oxidation and glucose utilization in left bundle branch block assessed with PET.
    Altehoefer C; vom Dahl J; Bares R; Stöcklin GL; Büll U
    J Nucl Med; 1995 Nov; 36(11):2056-9. PubMed ID: 7472598
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of myocardial ischemia using a rest metabolism/stress perfusion protocol with fluorine-18 deoxyglucose/technetium-99m MIBI and dual-isotope simultaneous-acquisition single-photon emission computed tomography.
    Sandler MP; Videlefsky S; Delbeke D; Patton JA; Meyerowitz C; Martin WH; Ohana I
    J Am Coll Cardiol; 1995 Oct; 26(4):870-8. PubMed ID: 7560611
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Positron tomography and myocardial metabolism: an overview.
    Sobel BE
    Circulation; 1985 Nov; 72(5 Pt 2):IV22-30. PubMed ID: 3931935
    [No Abstract]   [Full Text] [Related]  

  • 31. Use and limitations of metabolic tracers labeled with positron-emitting radionuclides in the identification of viable myocardium.
    Bergmann SR
    J Nucl Med; 1994 Apr; 35(4 Suppl):15S-22S. PubMed ID: 8151408
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Accumulation of fluorodeoxyglucose in ischemic myocardium. I. Comparison with myocardial perfusion at rest and during exercise].
    Yonekura Y; Senda M; Koide H; Saji H; Yamamoto K; Nishizawa S; Torizuka K; Fudo T; Hashimoto T; Kambara H
    Kaku Igaku; 1986 Oct; 23(10):1361-7. PubMed ID: 3493371
    [No Abstract]   [Full Text] [Related]  

  • 33. Fluorine-18-fluorodeoxyglucose PET to determine regional cerebral glucose utilization: a re-examination.
    Schmidt KC; Lucignani G; Sokoloff L
    J Nucl Med; 1996 Feb; 37(2):394-9. PubMed ID: 8667082
    [No Abstract]   [Full Text] [Related]  

  • 34. Features of positron emission tomography as a probe for myocardial chemistry.
    Schelbert HR
    Eur J Nucl Med; 1986; 12 Suppl():S2-10. PubMed ID: 3490372
    [No Abstract]   [Full Text] [Related]  

  • 35. Improved detection of viable myocardium with fluorodeoxyglucose-labeled single-photon emission computed tomography in a patient with hibernating myocardium: comparison with rest-redistribution thallium 201-labeled single-photon emission computed tomography.
    Bax JJ; Visser FC; Cornel JH; van Lingen A; Fioretti PM; Visser CA
    J Nucl Cardiol; 1997; 4(2 Pt 1):178-9. PubMed ID: 9115073
    [No Abstract]   [Full Text] [Related]  

  • 36. Effect of nicotinic acid on exogenous myocardial glucose utilization.
    Stone CK; Holden JE; Stanley W; Perlman SB
    J Nucl Med; 1995 Jun; 36(6):996-1002. PubMed ID: 7769458
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Myocardial metabolic changes in hypertrophic cardiomyopathy.
    Tadamura E; Tamaki N; Matsumori A; Magata Y; Yonekura Y; Nohara R; Sasayama S; Yoshibayashi M; Kamiya T; Konishi J
    J Nucl Med; 1996 Apr; 37(4):572-7. PubMed ID: 8691242
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The comparison of 2-18F-2-deoxyglucose and 15-(ortho-123I-phenyl)-pentadecanoic acid uptake in persisting defects on thallium-201 tomography in myocardial infarction.
    Henrich MM; Vester E; von der Lohe E; Herzog H; Simon H; Kuikka JT; Feinendegen LE
    J Nucl Med; 1991 Jul; 32(7):1353-7. PubMed ID: 2066789
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Myocardial viability. What does it mean and how do we measure it?
    Gould KL
    Circulation; 1991 Jan; 83(1):333-5. PubMed ID: 1984890
    [No Abstract]   [Full Text] [Related]  

  • 40. Effect of the duration of fasting on myocardial fluorine-18-fluorodeoxyglucose positron emission tomography images in normal males.
    Yamanouchi M; Yoshida K; Niwayama H; Nakagawa K; Aioi S; Shikama N; Himi T; Imazeki K; Itoh Y; Masuda Y
    Jpn Circ J; 1996 Jun; 60(6):319-27. PubMed ID: 8844297
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.